Drozitumab Biosimilar, TRAIL Monoclonal Antibody

Drozitumab Biosimilar uses the same protein sequences as the therapeutic antibody drozitumab. Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Immunogen	Death receptor DR5 and induces apoptosis
Clone	Drozitumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	143.06 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered solution, pH 6.0